BiotechTube

DFV890 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Symptomatic Knee Osteoarthritis

Conditions

Symptomatic Knee Osteoarthritis

Trial Timeline

Sep 20, 2021 → Dec 23, 2024

NCT ID
NCT04886258

About DFV890 + Placebo

DFV890 + Placebo is a phase 2 stage product being developed by Novartis for Symptomatic Knee Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04886258. Target conditions include Symptomatic Knee Osteoarthritis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT06031844Phase 2Completed
NCT04886258Phase 2Completed

Competing Products

20 competing products in Symptomatic Knee Osteoarthritis

See all competitors
ProductCompanyStageHype Score
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
77
ISV-305Sun PharmaceuticalPhase 3
77
rabeprazole sodium + PlaceboEisaiPhase 3
77
Verinurad + Febuxostat + DapagliflozinAstraZenecaPhase 2
52
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
41
Esomeprazole + Matching placeboAstraZenecaPhase 3
77
Omalizumab + Omalizumab + PlaceboNovartisPhase 2
52
Pasireotide + OctreotideNovartisPhase 3
77
TegaserodNovartisPhase 2
52
valsartanNovartisApproved
85
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
22
Epoetin biosimilarPfizerPre-clinical
22
Apixaban + Standard of carePfizerPhase 3
76
Azithromycin plus chloroquinePfizerPhase 3
76
MavacamtenBristol Myers SquibbApproved
84
Aficamten + PlaceboSanofiPhase 3
76
Vandetanib 300 mgSanofiPre-clinical
22
REGN7508 + Acetylsalicylic Acid (ASA) + PlaceboRegeneron PharmaceuticalsPhase 3
76
Rivaroxaban + PlaceboBayerPhase 3
74
Droxidopa capsules + Placebo capsulesLundbeckApproved
82

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85